Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Open accessThe DOI matches its Crossref record.
Abstract
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease and hepatocellular carcinoma. There have been rapid advances in HCV treatment with the development of oral direct-acting antivirals (DAAs). Studies have shown sustained virological response rates above 90% with combinations of DAAs, including patients with compensated cirrhosis. Thus far, significant drug toxicity has not been seen with these agents, but there is limited experience of using DAAs in decompensated HCV cirrhosis. This report describes the first experience of serious drug-induced hepatotoxicity with the new DAAs. The mechanism underlying these drug reactions is currently unknown. Few patients with decompensated cirrhosis have been treated with DAAs, so the exact pharmacokinetics in this population have not been characterised. In both cases presented here, patients were taking or had recently taken other drugs. It is possible that an unknown interaction or reaction to the drug combination caused the hepatotoxicity. Although the association with the DAAs is not proven these cases indicate that patients with advanced liver disease need close monitoring while on DAA therapy and if there is a significant unexplained deterioration in liver function the DAAs should be discontinued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Curry, M. P., O’Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., Reddy, K. R., Lawitz, E., Flamm, S. L., Schiano, T., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512614 · Cited by 804
RUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
Foster, G. R., Irving, W. L., Cheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.029 · Cited by 492
Self-citationHepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C
Hoofnagle, J. H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.007 · Cited by 31
Shahbaz, O., Mahajan, S., & Lewis, J. H. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1362391 · Cited by 30
Metadata
- Authors
- Dyson, J. K., Hutchinson, J., Harrison, L., Rotimi, O., Tiniakos, D., Foster, G. R., Aldersley, M. A., & McPherson, S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 64
- Issue
- 1
- Pages
- 234-238
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1204921410
- Cited by
- 96
- References
- 0
- FWCI
- 10.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. https://app.cochat.ai/papers/10.1016/j.jhep.2015.07.041
- The paper
- Dyson, J. K., Hutchinson, J., Harrison, L., Rotimi, O., Tiniakos, D., Foster, G. R., Aldersley, M. A., & McPherson, S. (2016). Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2015.07.041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.